News and Events

Programs and providers of Obstetrics and Gynecology at Weill Cornell Medicine are often the focus of news stories and features appearing in major national media. We invite you to review some stories that typify the breakthrough accomplishments of our remarkable team and highlight the impact our care has had on patient’s lives.

Reprogramming Gut Cells to Treat Short Bowel Syndrome

reprogramming gut cells

Knocking out a single gene reprograms part of the large intestine to function like the nutrient-absorbing small intestine. In a preclinical study, Weill Cornell Medicine investigators showed that the technique reversed the malnutrition that results when most of the small intestine is removed. The successful demonstration suggests that a similar strategy could be used to treat short bowel syndrome, a life-threatening disorder that can occur when very little of the small intestine remains after surgery to address chronic inflammation, cancer, trauma or congenital conditions.

Dr. Xiaofeng Huang

Dr. Xiaofeng Huang

Trial Shows Targeted Treatment for Childhood Brain Tumor is Safe

DIPG

A Phase I clinical trial demonstrated that a targeted approach to treating a deadly brain tumor in children called diffuse intrinsic pontine glioma (DIPG) is safe, reported Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center investigators. This is the first larger scale study using a radiation-based direct drug delivery approach to treat and image DIPG.

DIPG is an aggressive cancer without any effective treatment—fewer than 10% of children survive two years after diagnosis. The tumor embeds itself into the brainstem that regulates vital functions, including breathing, heart rate and muscle control. Neither chemotherapy drugs nor surgery can reach the tricky location at the base of the brain.

The new study, published Feb. 19 in Neuro-Oncology, established that infusing a drug called 124I-Omburtamab directly into the brainstem is a safe way to maximize delivery of the drug right where DIPG tumors develop—without poisoning the rest of the body.

Omega-6 Fatty Acid Promotes the Growth of an Aggressive Type of Breast Cancer

line of vegetable oils in industrial setting

Linoleic acid, an omega-6 fatty acid found in seed oils such as soybean and safflower oil, and animal products including pork and eggs, specifically enhances the growth of the hard-to-treat “triple negative” breast cancer subtype, according to a preclinical study led by Weill Cornell Medicine investigators. The discovery could lead to new dietary and pharmaceutical strategies against breast and other cancers.

In the study, published March 14 in Science, the researchers found that linoleic acid can activate a major growth pathway in tumor cells by binding to a protein called FABP5. Comparing breast cancer subtypes, the team observed that this growth pathway activation occurs in triple-negative tumor cells, where FABP5 is particularly abundant, but not in other hormone-sensitive subtypes. In a mouse model of triple-negative breast cancer, a diet high in linoleic acid enhanced tumor growth.

“This discovery helps clarify the relationship between dietary fats and cancer, and sheds light on how to define which patients might benefit the most from specific nutritional recommendations in a personalized manner,” said study senior author Dr. John Blenis, the Anna-Maria and Stephen Kellen Professor of Cancer Research in the Department of Pharmacology and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.